Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

New superbug test developed by TGen-NAU receives Australian patent

New superbug test developed by TGen-NAU receives Australian patent

Antibiotic-resistant infections should be easier to detect, and hospitals could become safer, thanks to a technology developed by the Translational Genomics Research Institute and Northern Arizona University, and protected under a patent issued by Australia. [More]
Topical delivery of AVR drug combination can provide complete protection against HIV

Topical delivery of AVR drug combination can provide complete protection against HIV

Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV. [More]
Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data. [More]
Coagadex now available for rare bleeding disorder patients in the UK

Coagadex now available for rare bleeding disorder patients in the UK

Bio Products Laboratory, Limited (BPL) today announced that Coagadex is now available for patients in the UK. [More]
NHS England takes too long to commission PrEP for HIV prevention

NHS England takes too long to commission PrEP for HIV prevention

An effective treatment that can prevent HIV infection and reduce the human and financial costs of the preventable condition is taking too long to be commissioned and made available on the NHS, warns Deborah Gold, chief executive of the National Aids Trust, in an article published by The BMJ today. [More]
Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Simple, cheap chemical sensors may detect developing cancers in future

Simple, cheap chemical sensors may detect developing cancers in future

Many cancers could be successfully treated if the patient consulted the doctor sufficiently early. But how can a developing cancer be detected if it doesn't give rise to any symptoms? In the near future, suitably early diagnosis could be provided by simple and cheap chemical sensors - thanks to special recognizing polymer films developed at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw. [More]
New antibody-based therapy may provide better strategy for long-term control of HIV

New antibody-based therapy may provide better strategy for long-term control of HIV

The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection. What was once a certain death sentence is now a chronic condition that people can live with for decades. [More]
Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016. [More]
European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. [More]
Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Subcutaneous injection of raltegravir can protect against vaginal HIV transmission

Vaginal transmission accounts for the majority of new HIV infections worldwide. Forms of pre-exposure prophylaxis (PrEP) such as vaginal gels and vaginal rings designed to prevent HIV transmission have encountered poor efficacy in human trials due to problems with adherence. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
VTE patients tend to die earlier from bladder cancer

VTE patients tend to die earlier from bladder cancer

In a study of 3879 patients who underwent radical cystectomy to treat bladder cancer, 3.6% were diagnosed with a venous thromboembolism (VTE)—which occurs when a blood clot forms in a vein, potentially breaking loose and traveling to the lung—within 1 month of their surgical admission date. [More]
Idelvion approved for use in children and adults with Hemophilia B

Idelvion approved for use in children and adults with Hemophilia B

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. [More]
Women need antiviral medication Truvada more than men to prevent HIV infection

Women need antiviral medication Truvada more than men to prevent HIV infection

Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill. [More]
Dating sites helping spread HIV, study finds

Dating sites helping spread HIV, study finds

More than 60 percent of Rhode Island men who have sex with men (MSM) diagnosed with HIV in 2013 reported meeting sexual partners online in the preceding year, according to a study published today in the journal Public Health Reports. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV. [More]
Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

Single dose of zoledronic acid can inhibit bone loss in HIV-infected patients

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART). [More]
Advertisement
Advertisement